BridgeBio Pharma (BBIO) Total Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $3.6 billion for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $3.6 billion, up 44.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 44.43% YoY), and the FY2025 annual result was $3.0 billion, up 26.75% from the prior year.
• Total Non-Current Liabilities came in at $3.6 billion for Q1 2026 at BridgeBio Pharma, up from $3.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.6 billion in Q1 2026 to a low of $1.8 billion in Q1 2023.
• The 5-year median for Total Non-Current Liabilities is $1.9 billion (2024), against an average of $2.2 billion.
• Across the five-year window, Total Non-Current Liabilities decreased 0.81% in 2022 and jumped 55.09% in 2025, its largest moves.
• BridgeBio Pharma's Total Non-Current Liabilities stood at $1.8 billion in 2022, then increased by 2.28% to $1.9 billion in 2023, then rose by 26.2% to $2.4 billion in 2024, then climbed by 26.75% to $3.0 billion in 2025, then increased by 20.82% to $3.6 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.6 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.